New Biomarker Data from TACTI-002 trial in 1st line NSCLC
Filed with ASX · · 3 pages · English
• Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes • Early increase in absolute lymphocyte count is correlated with the positive Overall Survival results in nonsmall cell lung cancer patients recently reported at ESMO 2023, and is a pot
Story so far
Earlier from Immutep
- Immutep reports promising data from INSIGHT-003 trial
- Webcast slides for new Efti clinical data in 1st line NSCLC
- Excellent Overall Survival in Non-Small Cell Lung Cancer
- Immutep announces publication of ESMO 2023 abstracts
- Commercial Scale Manufacturing of Efti for Clinical Trials
Later from Immutep
- Lead-in phase completed for ph2/3 trial in Breast Cancer
- Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
- Immutep receives A$2.6 million French R&D Tax Incentive
- PEI provides constructive feedback for ph3 lung cancer trial
- First Clinical Data announced from 90mg Dosing of Efti
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep